Nasdaq · Healthcare
Viatris Inc (VTRS)
As-reported financials and recent SEC filings for Viatris Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$14.25B
Net income
$-3.51B
Net margin
-24.7%
Diluted EPS
$-3.00
ROE
-23.9%
P/E (TTM)
—
Market cap
$19.02B
Debt / equity
0.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.25B | $14.69B | $15.39B | $16.22B | $17.81B |
| Gross profit | $4.96B | $5.58B | $6.40B | $6.45B | $5.50B |
| Operating income | $-2.66B | $10.1M | $766.2M | $1.61B | $-34.0M |
| Net income | $-3.51B | $-634.2M | $54.7M | $2.08B | $-1.27B |
| Diluted EPS | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →8-K2026-06-18
View on EDGAR →8-K2026-06-15
View on EDGAR →424B52026-06-15
View on EDGAR →FWP2026-06-12
View on EDGAR →424B52026-06-12
View on EDGAR →8-K2026-05-15
View on EDGAR →Go deeper on VTRS
Search Viatris Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.